GSK's vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programm
Pfizer is aiming to be first on the grid in the race to being a vaccine against respiratory syncytial virus (RSV) to market, after reporting results from a phase 3 trial of the jab in older
The EMA's Emergency Task Force (ETF) has recommended that EU member states can use a different regimen for Bavarian Nordic's monkeypox vaccine Imvanex/Jynneos that uses a smaller dose, to e
Monkeypox has claimed the first lives outside Africa – one in Brazil and another two in Spain – although the World Health organization (WHO) has said the outbreak remains "containable."
The EMA has extended the approved indications of Bavarian Nordic's smallpox vaccine Imvanex for monkeypox, which has now infected tens of thousands of people across dozens of countries worl
GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated AReSVi 006 trial in ad